Long‐Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder
Addiction Biology · 2026-05 · 31 (5)
DOI: 10.1111/adb.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction Biology, online erschienen am 17.05.2026. Verfasst von Lindsey M Brier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Studies of Addiction, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Naltrexone, Marijuana Abuse, Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Commonwealth of Pennsylvania CURE Addiction Center of Excellence, NIH HHS, NIAAA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Comorbid substance use disorders ( SUDs ) are common but difficult to study due to the complex, interacting and overlapping mechanisms through which they affect brain networks. Many datasets collected to investigate a specific SUD include participants with comorbid SUDs. Although most studies treat comorbid SUDs as covariates of no interest, these covariates also contain untapped information. This is particularly relevant as cannabis use disorder ( CanUD ) has become increasingly prevalent and comorbid with other SUDs that have been more thoroughly studied. While pharmacotherapies have been established for multiple SUDs, none have been approved for CanUD, although naltrexone ( NTX ) has been associated with reduced use. Here, we conducted a retrospective secondary analysis of functional magnetic resonance imaging ( fMRI ) data from individuals with primary opioid use disorder ( OUD‐only , N = 25 pre‐NTX, N = 20 on‐NTX) with comorbid CanUD ( N = 10), alcohol use disorder ( AUD , N = 6) or cocaine use disorder ( CocUD , N = 7). All participants underwent imaging prior to receiving a therapeutic dose of long‐acting intramuscular NTX (Vivitrol), an approved treatment for OUD and AUD but not for CocUD, and again 2 weeks postadministration. At baseline, OUD individuals with comorbid CanUD, AUD or CocUD exhibited distinct functional connectivity ( FC ) alterations compared to those with OUD‐only. These differences were greater in younger participants and primarily involved the default mode network. Following NTX administration, FC differences between the comorbid CanUD and OUD‐only groups globally diminished. A similar FC response to NTX was observed in the comorbid AUD group, whereas little change in FC was observed in comorbid CocUD. These findings, combined with prior evidence that NTX reduces cannabis use by dampening reward, suggest NTX may hold promise as a treatment for CanUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Studies of Addiction, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Lindsey M Brier, Corinde E Wiers
Förderung
- Commonwealth of Pennsylvania CURE Addiction Center of Excellence
- NIH HHS
- NIAAA NIH HHS
- NIMH NIH HHS
- NIDA NIH HHS
- National Institutes of Health
Zitieren
APA
Brier, L. M., Langleben, D. D., Wiers, C. E., & Shi, Z. (2026). Long‐Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder. Addiction Biology, 31(5). https://doi.org/10.1111/adb.70159
Vancouver
Brier LM, Langleben DD, Wiers CE, Shi Z. Long‐Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder. Addiction Biology. 2026;31(5). doi:10.1111/adb.70159
BibTeX
@article{Brier2026,
author = {Brier, Lindsey M and Langleben, Daniel D and Wiers, Corinde E and Shi, Zhenhao},
title = {Long‐Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder},
journal = {Addiction Biology},
year = {2026},
volume = {31},
number = {5},
doi = {10.1111/adb.70159}
}
EUVIMED